Remove Definition Remove Pharma Companies Remove Pharmaceuticals
article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. Looking ahead, 2025 could represent a major turning point for the pharmaceutical sector.

article thumbnail

#Unshackled: The evolving definition of asset-centricity

DrugBaron

Over the next few years, the practice of asset-centric investing was honed through various iterations all designed to counter the inherent progression bias that damages returns in pharmaceutical R&D. Doing that allowed the creation of new tools that are appropriate to deploy much later in the pharmaceutical R&D process.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Re-Imagining Med Chem Strategies: the Tyranny of the n+1 Compound

DrugBaron

That’s the part of the process that’s analgous to the library evolution phase of Galaxy The classical approach beloved of large pharma companies is really a brute-force method: make as many molecules as you can to assemble the SAR. Definitely not just more compounds per week. Not just more data per week.

article thumbnail

Darkest Before Dawn: A Story Of Biotech Optimism In A Tough Market

LifeSciVC

One can’t always control the former, but the latter is definitely within our power to shape. We had a significantly limited set of Phase 1B data in psoriasis patients for TYK2 at the time, and we were now free to speak to pharma companies interested in our TYK2 program. At the Board meeting in early 2022, we were scrambling.

article thumbnail

Q&A: The IND Journey Phase I – Navigating Success

Advarra

The sponsor is the pharmaceutical company conducting the trial. A: Working in a pharmaceutical company is the best way to learn this. Each company will have its own processes, but they will all have the same result. The sponsor-initiated IND is conducted by a pharma company seeking commercial approval.

article thumbnail

First in Human Episode #54 featuring Ahmed Hamdy

Vial

Explore the groundbreaking VersAptx bioconjugation platform, designed to elevate cancer therapies and uncover the delicate balance between clinical excellence and commercial viability in the dynamic landscape of pharmaceuticals. In our drug CDK9 inhibitors inhibit Myc profoundly along with other messenger RNAs like MCL-1.

article thumbnail

Combo ‘Polypill’ May Cut Heart Attack, Stroke Risk Up to 40%

The Pharma Data

“When you look at the combination of aspirin and the polypill, you definitely see a meaningful reduction in cardiovascular events,” said Dr. Eugene Yang, chair-elect of the American College of Cardiology’s Prevention of Cardiovascular Disease Council. © 2020 HealthDay.